Funding
Convertible financing · Biotech

Novadip secures €10.4m convertible financing for Phase 3

New Science Ventures led the financing to advance NVD-003 and prepare a US Biologics License Application.

Updated Oct 18, 2026By RoundOS Funding desk

Fund+, VIVES Fund, ORSA Tech, Invest.BW, Noshaq, Sambrinvest and Wallonie Entreprendre also participated.

The capital will support NVD-003 through its pivotal Phase 3 trial for congenital pseudarthrosis of the tibia and preparation of a US regulatory submission.

Use of funds

Advance NVD003 through its pivotal Phase 3 trial and prepare the US Biologics License Application

Funding history

Convertible financing · This round€10.4M

Sources

  1. Novadip secures €10.4 million financing to complete pivotal Phase 3 trialnovadip.com · Sep 21, 2026
  2. novadip.com
  3. novadip.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related